Real-World Skin Clearance and Quality of Life with risankizumab in Patients with Psoriasis with Moderate Skin Involvement and Those Eligible for Systemic Therapy Per International Psoriasis Council Classification

By afschroeder • July 2, 2025

Strober B, Patel M, Kaldas MI, St John G, Photowala H, Sima AP, Eckmann T, Beeghly A, Armstrong A. Real-World Skin Clearance and Quality of Life with risankizumab in Patients with Psoriasis with Moderate Skin Involvement and Those Eligible for Systemic Therapy Per International Psoriasis Council Classification. Dermatol Ther (Heidelb). 2025 Jul 2. doi: 10.1007/s13555-025-01474-3. Epub ahead of print. PMID: 40593269.

Tags: CorEvitas Psoriasis Registry, Dermatology, International Psoriasis Council disease reclassification, National Psoriasis Foundation treat-to-target goals, patient-reported outcomes, psoriasis, Publications, real-world, risankizumab, Skin clearance, Systemic-eligible

International development of Investigator Global Assessment scores for pemphigus

Murrell DF, Boucher D, Daneshpazhooh M, Mahmoudi H, Kianfar N, Dasdar S, Yale M, Wilson A, Bilgic A, Uzun S, Chandran NS, Patsatsi A, Drenovska[...]

Envudeucitinib, a Potent, Next-Generation, Allosteric Inhibitor of TYK2: A Narrative Review

Armstrong AW, Krueger JG, Strober BE, Stein Gold LF, Desai SR, Muscianisi E, Klyachkin Y, Ucpinar S, Tilley MK, Blauvelt A. Envudeucitinib, a Potent, Next-Generation,[...]

Incubating Artificial Intelligence (AI) Initiatives and Careers in Dermatology

Wongvibulsin S, Primiero CA, Adamson AS, Barata C, Betz-Stablein B, Celebi ME, Dawant B, Guitera P, Kelly KM, Kittler H, Kose K, Landman B, Lehman[...]